Why Cost Segregation Is a Strategic Tax Tool for Life Science Companies 

The life sciences sector is uniquely capital-intensive, highly regulated, and driven by continuous innovation. Pharmaceutical manufacturers, biotechnology firms, medical device companies, and contract research organizations (CROs) routinely invest tens or hundreds of millions of dollars into highly specialized facilities designed to support research, testing, manufacturing, and quality assurance activities. 

While tax planning conversations in life sciences frequently center on the R&D tax credit, orphan drug incentives, and transaction structuring, cost segregation remains one of the most effective tools for improving after-tax cash flow and accelerating return on invested capital. 

When executed correctly, cost segregation complements other federal incentives, such as the R&D Tax Credit, the §179D Energy-Efficient Commercial Building Deduction, and the Orphan Drug Tax Credit (ODTC), to create a layered tax strategy tailored to life science organizations. 

Understanding Cost Segregation in a Life Sciences Context 

Cost segregation is an engineering-based tax analysis that dissects a building’s construction or acquisition costs to identify components eligible for shorter recovery periods under the Internal Revenue Code (IRC). Instead of depreciating an entire facility over 39 years, qualifying assets are reclassified into 5-, 7-, or 15-year property, accelerating depreciation deductions under IRC §168. 

For life science companies already leveraging incentives such as the R&D Tax Credit (for qualified research activities and related wage/supply costs), cost segregation introduces a complementary lever: non-credit depreciation deductions that reduce taxable income and improve near-term cash flow. 

Why Life Science Facilities Are Ideal Candidates 

The cost per square foot associated with equipping a life sciences property is higher than that associated with fitting out any other type of commercial real estate. This makes the sector one of the highest-leverage candidates for cost segregation. 

Life science buildings are purpose-built environments engineered around scientific precision, regulatory compliance, and process-driven design. These characteristics distinguish them from conventional commercial properties and materially expand cost segregation opportunities. 

Typical features include: 

From a tax standpoint, many of these assets can be treated as personal property (rather than structural components) when they are installed primarily to support equipment, processes, or specialized operational requirements. 

High-Value Asset Categories Common in Life Science Cost Segregation 

1. Specialized HVAC and Environmental Control Systems 

Life science facilities often require HVAC systems that exceed standard building requirements due to cleanroom classification, product stability requirements, or compliance-driven environmental parameters. These may include:

When these systems serve specific labs, suites, or controlled zones, portions can often be classified into shorter recovery lives, particularly where design intent is process-driven rather than general occupant comfort. 

Internal cross-link opportunity: These same HVAC and lighting efficiency upgrades may also support eligibility under the §179D Energy-Efficient Commercial Building Deduction, enabling a coordinated approach between energy incentives and depreciation planning. 

2. Laboratory Build-Outs and Process Infrastructure 

Laboratory-intensive environments represent some of the strongest cost segregation value drivers for life sciences. Reclassifiable assets often include: 

Because these assets are designed to support R&D operations, they commonly align with documentation and technical narratives already developed for the R&D Tax Credit, creating efficiency in substantiation and data collection. 

3. Cleanrooms and Controlled Manufacturing Environments 

Cleanrooms, especially in pharmaceutical, biologics, and medical device production are frequently among the most tax-efficient components of life science facilities when analyzed through cost segregation. 

Eligible components may include:

These assets are often product-line specific, removable, or directly tied to operational processes, which can strengthen support for classification as personal property. 

4. Electrical, Data, and Automation Systems 

Life science operations demand electrical and data infrastructure beyond standard commercial requirements, including: 

The portion of these systems dedicated to equipment operation and specialized process support can often be segregated into shorter lives, depending on design intent and system allocation. 

5. Site and Exterior Improvements 

Life science campuses frequently include extensive site-level investments:

These costs are often eligible for 15-year depreciation as land improvements, accelerating cost recovery compared to default structural capitalization. 

Timing and Method Change Considerations (Without Relying on Bonus Depreciation) 

Cost segregation can deliver value in multiple scenarios:

For life science organizations that scale quickly or frequently reconfigure space to meet program and pipeline needs, proactive cost segregation planning can prevent value leakage by ensuring asset classes are documented and captured correctly at the time of placement in service. 

One Big Beautiful Bill Act (2025), A Game Changer 

The OBBBA introduces significant changes to 100% bonus depreciation, making it permanent for most property acquired after January 19, 2025, and establishing a new temporary allowance for qualified production property, defined as non-residential building property with a 39-year depreciable life used integrally in qualified production activities and placed in service in the U.S. This is particularly impactful for pharma and medtech manufacturers building or expanding domestic facilities. 

Integrating Cost Segregation with Broader Life Science Tax Strategy 

Cost segregation is strongest when evaluated as part of a portfolio-wide incentive strategy. For life science companies, that often includes:

Internal cross-link opportunity: If you’re already evaluating ODTC impacts in late-stage valuations and deal models, cost segregation can improve after-tax cash flow projections by accelerating depreciation recovery on specialized facilities supporting clinical and commercial scale-up. 

IRS Scrutiny and the Importance of Technical Rigor 

Given the complexity and dollar magnitude of life science facilities, cost segregation studies must be performed using a defensible, engineering-based methodology. Best practices include:

Studies lacking technical substantiation (or relying on overly broad heuristics) can increase audit exposure, especially in highly specialized environments like cleanrooms and regulated manufacturing suites. 

Conclusion: A Strategic Advantage for Life Science Organizations 

For many life science companies, cost segregation remains an overlooked opportunity, often due to misconceptions about eligibility or perceived complexity. In reality, the very features that make life science facilities expensive to build also make them prime candidates for accelerated depreciation. 

For life science companies, cost segregation is a capital efficiency tool disguised as a tax strategy. The specialized, high-cost nature of lab and manufacturing buildouts means more assets qualify for reclassification than in almost any other property type. Combined with permanent 100% bonus depreciation under the OBBBA, the program can meaningfully accelerate cash return on capital, which is especially critical for pre-revenue biotech firms burning through capital on R&D and infrastructure simultaneously. 

When strategically integrated with R&D credits, §179D energy incentives, and (where applicable) orphan drug incentives, cost segregation becomes a powerful lever for improving cash flow, increasing capital efficiency, and supporting innovation-driven growth.